A. Qin

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

Charles A. Powell, Shanu Modi, Hiroji Iwata et al. · ESMO Open · 2022 · 231 citations · Full text

Medicine, Oncology, Pharmacology +12

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

Andrew J. Wagner, Hedy L. Kindler, Hans Gelderblom et al. · Annals of Oncology · 2016 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

Geoffrey Y. Ku, Maria Di Bartolomeo, E.C. Smyth et al. · Annals of Oncology · 2022 · 30 citations · Full text

Medicine, Oncology, Metastasis +16

LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen

Eric Van Cutsem, Maria Di Bartolomeo, E.C. Smyth et al. · Annals of Oncology · 2021 · 28 citations

Medicine, Oncology, Pharmacotherapy +17

289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies

Charles A. Powell, D. Ross Camidge, Shanu Modi et al. · Annals of Oncology · 2020 · 21 citations

Medicine, Clinical Sciences, Oncology +8